Inavolisib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.
Journal: Neoplasia (New York, N.Y.)
Published: April 01, 2026
A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.
Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026
Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 17, 2025
The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: December 08, 2025
Inavolisib plus fulvestrant-palbociclib - advanced or metastatic breast cancers hormone receptor-positive, HER2-negative, PIK3CA-mutated, endocrine-resistant, in the first-line setting
Journal: Bulletin du cancer
Published: November 09, 2025
Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China.
Journal: Frontiers in pharmacology
Published: November 09, 2025
Inavolisib-Based Therapy for PIK3CA-Mutated Advanced Male Breast Cancer: A Cost-Effectiveness Analysis.
Journal: Breast cancer (Dove Medical Press)
Published: September 25, 2025
Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: September 17, 2025
Disproportionality Analysis of Oral Toxicities Associated with PI3K/AKT/mTOR Pathway Inhibitors Using the FAERS Database.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: September 08, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 22, 2025
Last Updated: 04/28/2026